McGill IBD logo
Donate

MUHC Publications: November 2022 – November 2023

MUHC Activities

  1. In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Al-Jabri R, Afif W.Ann Intern Med. 2023 Jul;176(7):JC82. doi: 10.7326/J23-0048. Epub 2023 Jul 4.PMID: 37399559 Clinical Trial.
  2. Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. Gorodensky JH, Bernatsky S, Afif W, St-Pierre Y, Filion KB, Vinet É.J Rheumatol. 2023 Jul 1:jrheum.2022-1271. doi: 10.3899/jrheum.2022-1271. Online ahead of print.PMID: 37399458
  3. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. D’Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group (Afif W).N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940.PMID: 37379135 Clinical Trial.
  4. Serious Infections in Offspring Exposed in Utero to Vedolizumab. Gorodensky JH, Bernatsky S, Afif W, St-Pierre Y, Filion KB, Vinet É.Inflamm Bowel Dis. 2023 May 12:izad079. doi: 10.1093/ibd/izad079. Online ahead of print.PMID: 37172205
  5. Ustekinumab Safety in Pregnancy: A Comprehensive Review. Gorodensky JH, Bernatsky S, Afif W, Filion KB, Vinet É.Arthritis Care Res (Hoboken). 2023 Apr;75(4):930-935. doi: 10.1002/acr.24813. Epub 2022 Nov 16.PMID: 34748293 Review.
  6. Standardizing Scoring Conventions for Crohn’s Disease Endoscopy: An International RAND/UCLA Appropriateness Study.Khanna R, Ma C, Hogan M, Zou G, Bessissow T, Bressler B, Colombel JF, Danese S, Daperno M, East JE, Hookey L, Loftus EV Jr, McDonald JWD, Panaccione R, Peyrin-Biroulet L, Rutter M, Sands BE, Vermeire S, Rémillard J, McFarlane SC, Sandborn WJ, D’Haens GR, Feagan BG, Jairath V.Clin Gastroenterol Hepatol. 2023 Oct;21(11):2938-2950.e6. doi: 10.1016/j.cgh.2023.05.029. Epub 2023 Jun 10.PMID: 37308036
  7. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn’s disease: A Canadian multi-center study. Bessissow T, Narula N, Ma C, In TSH, Eberg M, Karra K, Jairath V; Canadian IBD Research Consortium.Dig Liver Dis. 2023 Sep 14:S1590-8658(23)00860-5. doi: 10.1016/j.dld.2023.08.042. Online ahead of print.PMID: 37716860
  8. Deep ulcers are associated with increased C-reactive protein in active ulcerative colitis. Rivière P, Le Chevillier A, Rullier A, Marty M, Schurr E, Lapuyade B, Célerier B, Fernandez B, Bessissow T, Treton X, Uzzan M, Poullenot F, Berger A, Zerbib F, Laharie D.Dig Liver Dis. 2023 Sep;55(9):1194-1200. doi: 10.1016/j.dld.2023.05.004. Epub 2023 May 25.PMID: 37244790
  9. Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Shehab M, Al Akram S, Hassan A, Alrashed F, Jairath V, Bessissow T.Inflamm Bowel Dis. 2023 Aug 4:izad119. doi: 10.1093/ibd/izad119. Online ahead of print.PMID: 37541185
  10. Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis. Alphonsus L, De Silva TA, Ma C, MacDonald JK, Hanzel J, Beaton M, Bessissow T, Kayal M, Sedano R, Singh S, Jairath V.Aliment Pharmacol Ther. 2023 Aug;58(3):268-282. doi: 10.1111/apt.17568. Epub 2023 May 29.PMID: 37246609 Review.
  11. Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case series. Mahajna H, Verstockt B, Bergemalm D, Castiglione F, Rodríguez-Moranta F, Savarino E, Hoentjen F, Bessissow T, Pokryszka J, Cremer A, Eder P, Truyens M, Yerushalmy-Feler A, García MJ, Kopylov U.J Crohns Colitis. 2023 May 3;17(5):722-727. doi: 10.1093/ecco-jcc/jjac179.PMID: 36455965
  12. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study. Ma C, Panaccione R, Xiao Y, Khandelwal Y, Murthy SK, Wong ECL, Narula N, Tsai C, Peerani F, Reise-Filteau M, Bressler B, Starkey SY, Loomes D, Sedano R, Jairath V, Bessissow T; Canadian IBD Research Consortium.Am J Gastroenterol. 2023 May 1;118(5):861-871. doi: 10.14309/ajg.0000000000002129. Epub 2022 Dec 14.PMID: 36580497 Free PMC article.
  13. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn’s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Shehab M, Alrashed F, Heron V, Restellini S, Bessissow T.Inflamm Bowel Dis. 2023 Mar 1;29(3):367-375. doi: 10.1093/ibd/izac103.PMID: 35604382
  1. Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study. Shehab M, Alali A, Al-Hindawi A, Alsayegh A, Aldallal U, Abdullah I, Albaghli A, Alrashed F, Alfadhli A, Bessissow T.Front Med (Lausanne). 2023 Jan 6;9:1045661. doi: 10.3389/fmed.2022.1045661. eCollection 2022.PMID: 36687448 Free PMC article.
  2. Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study. Buie MJ, Coward S, Shaheen AA, Holroyd-Leduc J, Hracs L, Ma C, Panaccione R, Benchimol EI, Bernstein CN, Bitton A, Otley AR, Jones JL, Murthy SK, Ellen Kuenzig M, Peña-Sánchez JN, Targownik LE, Singh H, Avina-Zubieta A, Kaplan GG.Inflamm Bowel Dis. 2023 Oct 3;29(10):1536-1545. doi: 10.1093/ibd/izad020.PMID: 36917200 Free PMC article.
  3. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors. Shaffer SR, Kuenzig ME, Windsor JW, Bitton A, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Tandon P, St-Pierre J, Natt N, Davis T, Weinstein J, Im JHB, Benchimol EI, Kaplan GG, Goddard Q, Gorospe J, Bergevin M, Silver K, Bowles D, Stewart M, Pearlstein M, Dawson EH, Bernstein CN.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. eCollection 2023 Sep.PMID: 37674503 Free PMC article.
  4. The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD. Murthy SK, Kuenzig ME, Windsor JW, Matthews P, Tandon P, Benchimol EI, Bernstein CN, Bitton A, Coward S, Jones JL, Kaplan GG, Lee K, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Meka S, Chis RS, Gupta S, Cheah E, Davis T, Weinstein J, Im JHB, Goddard Q, Gorospe J, Loschiavo J, McQuaid K, D’Addario J, Silver K, Oppenheim R, Singh H.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S83-S96. doi: 10.1093/jcag/gwad006. eCollection 2023 Sep.PMID: 37674502 Free PMC article.
  5. The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape. Murthy SK, Weizman AV, Kuenzig ME, Windsor JW, Kaplan GG, Benchimol EI, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Sabrie N, Gupta S, Brar G, Khan R, Im JHB, Davis T, Weinstein J, St-Pierre J, Chis R, Meka S, Cheah E, Goddard Q, Gorospe J, Kerr J, Beaudion KD, Patel A, Russo S, Blyth J, Blyth S, Charron-Bishop D, Targownik LE.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S97-S110. doi: 10.1093/jcag/gwad015. eCollection 2023 Sep.PMID: 37674501 Free PMC article.
  6. The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease. Graff LA, Geist R, Kuenzig ME, Benchimol EI, Kaplan GG, Windsor JW, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Peña-Sánchez JN, Targownik LE, Jannati N, Jones May T, Akhtar Sheekha T, Davis T, Weinstein J, Dahlwi G, Im JHB, Amankwah Osei J, Rohatinsky N, Ghandeharian S, Goddard Q, Gorospe J, Gertsman S, Louis M, Wagner R, Brass C, Sanderson R, Bernstein CN.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S64-S75. doi: 10.1093/jcag/gwad012. eCollection 2023 Sep.PMID: 37674499 Free PMC article.
  7. The 2023 Impact of Inflammatory Bowel Disease in Canada: The Influence of Sex and Gender on Canadians Living With Inflammatory Bowel Disease. Targownik LE, Bollegala N, Huang VH, Windsor JW, Kuenzig ME, Benchimol EI, Kaplan GG, Murthy SK, Bitton A, Bernstein CN, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Davis T, Weinstein J, Im JHB, Jannati N, Khan R, Matthews P, Jones May T, Tabatabavakili S, Jogendran R, Hazan E, Browne M, Meka S, Vukovic S, Jogendran M, Hu M, Osei JA, Wang GY, Sheekha TA, Dahlwi G, Goddard Q, Gorospe J, Nisbett C, Gertsman S, Sousa J, Morganstein T, Stocks T, Weber A, Seow CH.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S55-S63. doi: 10.1093/jcag/gwad011. eCollection 2023 Sep.PMID: 37674498 Free PMC article.
  8. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-Children and Adolescents with IBD. El-Matary W, Carroll MW, Deslandres C, Griffiths AM, Kuenzig ME, Mack DR, Wine E, Weinstein J, Geist R, Davis T, Chan J, Khan R, Matthews P, Kaplan GG, Windsor JW, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Goddard Q, Gorospe J, Verdugo J, Morin SA, Morganstein T, Banning L, Benchimol EI.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S35-S44. doi: 10.1093/jcag/gwad016. eCollection 2023 Sep.PMID: 37674497 Free PMC article.
  9. The 2023 Impact of Inflammatory Bowel Disease in Canada: Access to and Models of Care. Mathias H, Rohatinsky N, Murthy SK, Novak K, Kuenzig ME, Nguyen GC, Fowler S, Benchimol EI, Coward S, Kaplan GG, Windsor JW, Bernstein CN, Targownik LE, Peña-Sánchez JN, Lee K, Ghandeharian S, Jannati N, Weinstein J, Khan R, Im JHB, Matthews P, Davis T, Goddard Q, Gorospe J, Latos K, Louis M, Balche N, Dobranowski P, Patel A, Porter LJ, Porter RM, Bitton A, Jones JL.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S111-S121. doi: 10.1093/jcag/gwad007. eCollection 2023 Sep.PMID: 37674496 Free PMC article.
  10. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs. Kuenzig ME, Im JHB, Coward S, Windsor JW, Kaplan GG, Murthy SK, Benchimol EI, Bernstein CN, Bitton A, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Jones May T, Tabatabavakili S, Jogendran R, Weinstein J, Khan R, Hazan E, Browne M, Davis T, Goddard Q, Gorospe J, Latos K, Mason K, Kerr J, Balche N, Sklar A, Targownik LE.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S16-S22. doi: 10.1093/jcag/gwad009. eCollection 2023 Sep.PMID: 37674495 Free PMC article.
  11. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD. Kaplan GG, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, Coward S, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Ghandeharian S, Rohatinsky N, Weinstein J, Jones May T, Browne M, Jannati N, Tabatabavakili S, Im JHB, Meka S, Vukovic S, Davis T, Goddard Q, Gorospe J, Stocks T, Caplan L, Kanaan N, Stuart D, Ramsay T, Robinson KJ, Charron-Bishop D, Benchimol EI.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S76-S82. doi: 10.1093/jcag/gwad019. eCollection 2023 Sep.PMID: 37674494 Free PMC article.
  12. The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs. Kuenzig ME, Coward S, Targownik LE, Murthy SK, Benchimol EI, Windsor JW, Bernstein CN, Bitton A, Jones JL, Lee K, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Jogendran R, Meka S, Weinstein J, Jones May T, Jogendran M, Tabatabavakili S, Hazan E, Hu M, Osei JA, Khan R, Wang G, Browne M, Davis T, Goddard Q, Gorospe J, Latos K, Mason K, Kerr J, Balche N, Sklar A, Kaplan GG.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S23-S34. doi: 10.1093/jcag/gwad008. eCollection 2023 Sep.PMID: 37674493 Free PMC article.
  13. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD. Coward S, Benchimol EI, Kuenzig ME, Windsor JW, Bernstein CN, Bitton A, Jones JL, Lee K, Murthy SK, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Davis T, Weinstein J, Goddard Q, Bennett J, Caplan L, Bergevin M, Yang XY, Mason K, Sanderson R, Brass C, Kaplan GG.J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S9-S15. doi: 10.1093/jcag/gwad004. eCollection 2023 Sep.PMID: 37674492 Free PMC article.
  1. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary. Windsor JW, Kuenzig ME, Murthy SK, Bitton A, Bernstein CN, Jones JL, Lee K, Targownik LE, Peña-Sánchez JN, Rohatinsky N, Ghandeharian S, Im JHB, Davis T, Weinstein J, Goddard Q, Benchimol EI, Kaplan GG.J Can Assoc Gastroenterol. 2023 Jun 1;6(Suppl 2):S1-S8. doi: 10.1093/jcag/gwad003. eCollection 2023 Sep.PMID: 37674500 Free PMC article.
  2. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis. Leibovitzh H, Lee SH, Raygoza Garay JA, Espin-Garcia O, Xue M, Neustaeter A, Goethel A, Huynh HQ, Griffiths AM, Turner D, Madsen KL, Moayyedi P, Steinhart AH, Silverberg MS, Deslandres C, Bitton A, Mack DR, Jacobson K, Cino M, Aumais G, Bernstein CN, Panaccione R, Weiss B, Halfvarson J, Xu W, Turpin W, Croitoru K; Crohn’s and Colitis Canada (CCC) Genetic, Environmental, Microbial (GEM) Project Research Consortium. 2023 Aug;72(8):1462-1471. doi: 10.1136/gutjnl-2022-328421. Epub 2023 Feb 14.PMID: 36788016
  3. Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease. Ferru-Clément R, Boucher G, Forest A, Bouchard B, Bitton A, Lesage S, Schumm P, Lazarev M, Brant S, Duerr RH, McGovern DPB, Silverberg M, Cho JH; NIDDK IBD Genetics Consortium, iGenoMed Consortium; Ananthakrishnan A, Xavier RJ, Rioux JD, Des Rosiers C.Inflamm Bowel Dis. 2023 Jul 5;29(7):1024-1037. doi: 10.1093/ibd/izac281.PMID: 36662167
  4. Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Abrahami D, Pradhan R, Yin H, Yanofsky R, McDonald EG, Bitton A, Azoulay L. 2023 Jul;72(7):1288-1295. doi: 10.1136/gutjnl-2022-328866. Epub 2023 Jan 30.PMID: 36717221
  5. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A, Farkas B, Katsanos K, Michalopoylos G, Ribaldone DG, Attauabi M, Zhao M, Barak HA, Yanai H, Bezzio C, Rispo A, Castiglione F, Bar-Gil Shitrit A, Pugliese D, Armuzzi A, Savarino EV, Kolar M, Lukáš M, Chashkova E, Filip R, Rozieres A, Nancey S, Krznarić Ž, Schäfer E, Szamosi, Sarlós P, Franko M, Drobne D, Knyazev OV, Kagramanova AV, Limdi J, Wetwittayakhlang P, Lakatos PL, Maharshak N, Bannon L, Nyári T, Szepes Z, Farkas K; TFB Study Group; Molnár T.Inflamm Bowel Dis. 2023 Aug 5:izad135. doi: 10.1093/ibd/izad135. Online ahead of print.PMID: 37542737
  6. Declining trends of reoperations and disease behavior progression in Crohn’s disease over different therapeutic eras – a prospective population-based study from western Hungary between 1977-2020, data from the Veszprem cohort. Gonczi L, Lakatos L, Golovics PA, Ilias A, Pandur T, David G, Erdelyi Z, Szita I, Al Khoury A, Lakatos PL.J Crohns Colitis. 2023 Jul 9:jjad117. doi: 10.1093/ecco-jcc/jjad117. Online ahead of print.PMID: 37422727
  7. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, Wild G, Bitton A, Bessissow T,Lakatos PL.Dig Liver Dis. 2023 Jul 5:S1590-8658(23)00720-X. doi: 10.1016/j.dld.2023.06.022. Online ahead of print.PMID: 37419726
  8. Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study. Wetwittayakhlang P, Verdon C, Starr M, Hahn GD, Golovics PA, Bessissow T, Afif W, Wild G, Bitton A,Lakatos PL.Turk J Gastroenterol. 2023 Jun;34(6):603-610. doi: 10.5152/tjg.2023.22527.PMID: 37162506 Free PMC article.
  9. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers. Rivière P, Kanters C, Pellet G, Ni A, Hupé M, Aboulhamid N, Poullenot F, Bitton A, Zerbib F, Lakatos PL, Afif W, Laharie D, Bessissow T.Inflamm Bowel Dis. 2023 Jun 1;29(6):923-931. doi: 10.1093/ibd/izac167.PMID: 35917111
  10. Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras-Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020. Wetwittayakhlang P, Gonczi L, Lakatos L, Kurti Z, Golovics P, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.J Crohns Colitis. 2023 May 3;17(5):712-721. doi: 10.1093/ecco-jcc/jjac188.PMID: 36539328
  11. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials. Shehab M, Alrashed F, Alkazemi A, Lakatos PL, Bessissow T.Expert Rev Gastroenterol Hepatol. 2023 May;17(5):469-477. doi: 10.1080/17474124.2023.2194631. Epub 2023 Apr 10.PMID: 36961082
  12. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Gearry RB, Kappelman MD, Hart A, Pierik MJ, Andrews JM, Ng SC, D’Inca R, Munkholm P.Lancet Gastroenterol Hepatol. 2023 May;8(5):458-492. doi: 10.1016/S2468-1253(23)00003-1. Epub 2023 Mar 2.PMID: 36871566 Review.
  13. Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary. Lontai L, Kürti Z, Gonczi L, Komlódi N, Balogh F, Iliás Á, Lakatos PL.Turk J Gastroenterol. 2023 May;34(5):508-515. doi: 10.5152/tjg.2023.22339.PMID: 36620930 Free PMC article.
  14. Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977-2020. Wetwittayakhlang P, Gonczi L, Golovics PA, Kurti Z, Pandur T, David G, Erdelyi Z, Szita I, Lakatos L, Lakatos PL.J Clin Med. 2023 Apr 21;12(8):3026. doi: 10.3390/jcm12083026.PMID: 37109362 Free PMC article.
  15. Epidemiology, Treatment Strategy, Natural Disease Course and Surgical Outcomes of Patients with Ulcerative Colitis in Western Hungary – A Population-based Study Between 2007 and 2018: Data from the Veszprem County Cohort. Kurti Z, Gonczi L, Lakatos L, Golovics PA, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.J Crohns Colitis. 2023 Apr 3;17(3):352-360. doi: 10.1093/ecco-jcc/jjac142.PMID: 36125105
  16. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Makovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group (Lakatos PL). 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440.PMID: 35606090 Free PMC article.No abstract available.
  17. Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis: A Population-Based Cohort Between 1977-2020. Wetwittayakhlang P, Golovics PA, Gonczi L, Lakatos L, Lakatos PL; Veszprem Epidemiology Study Group.Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00230-6. doi: 10.1016/j.cgh.2023.03.022. Online ahead of print.PMID: 37004972 Free article.No abstract available.
  18. The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer. Wetwittayakhlang P, Tselekouni P, Al-Jabri R, Bessissow T,Lakatos PL.J Clin Med. 2023 Mar 22;12(6):2432. doi: 10.3390/jcm12062432.PMID: 36983432 Free PMC article.
  19. Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018. Gonczi L, Lakatos L, Kurti Z, Golovics PA, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.J Crohns Colitis. 2023 Mar 18;17(2):240-248. doi: 10.1093/ecco-jcc/jjac132.PMID: 36087109
  1. Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases. Kablawi D, Aljohani F, Palumbo CS, Restellini S, Bitton A, Wild G, Afif W, Lakatos PL, Bessissow T, Sebastiani G.Crohns Colitis 360. 2023 Feb 2;5(1):otad004. doi: 10.1093/crocol/otad004. eCollection 2023 Jan.PMID: 36846097 Free PMC article.
  2. Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study. Royston L, Isnard S, Berini CA, Bu S, Lakatos PL, Bessissow T, Chomont N, Klein M, Lebouché B, de Pokomandy A, Kronfli N, Costiniuk CT, Thomas R, Tremblay C, Boivin G, Routy JP.BMJ Open. 2023 Jan 23;13(1):e067640. doi: 10.1136/bmjopen-2022-067640.PMID: 36690406 Free PMC article.
  3. Patient-Centered Access to IBD Care: A Qualitative Study. Heisler C, Rohatinsky N, Mirza RM, Kits O, Zelinsky S, Veldhuyzen van Zanten S, Nguyen G, McCurdy J, MacMillan M, Lakatos PL, Targownik L, Fowler S, Rioux K, Jones J.Crohns Colitis 360. 2022 Nov 29;5(1):otac045. doi: 10.1093/crocol/otac045. eCollection 2023 Jan.PMID: 36777367 Free PMC article.
  4. Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study. Wetwittayakhlang P, Golovics PA, Khoury AA, Ganni E, Hahn GD, Cohen A, Wyse J, Bradette M, Bessissow T, Afif W, Wild G, Bitton A, Lakatos PL.J Gastrointestin Liver Dis. 2022 Dec 16;31(4):403-410. doi: 10.15403/jgld-4375.PMID: 36535055 Free article.
  5. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study. Lontai L, Gonczi L, Balogh F, Komlodi N, Resal T, Farkas K, Molnar T, Miheller P, Golovics PA, Schafer E, Szamosi T, Ilias A, Lakatos PL.Dig Liver Dis. 2022 Dec;54(12):1639-1645. doi: 10.1016/j.dld.2022.07.004..PMID: 35931624
  6. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Xiao Y, Benoit N, Sedano R, Jairath V, Narula N, McCurdy JD, Rosenfeld G, Afif W, Lakatos PL, Bessissow T.Dig Dis Sci. 2022 Nov;67(11):5213-5219. doi: 10.1007/s10620-022-07439-2. PMID: 35244825
  7. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O’Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L.Clin Gastroenterol Hepatol. 2022 Nov;20(11):2619-2627.e1. doi: 10.1016/j.cgh.2022.02.032.PMID: 35189386

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate